JAMES B. BREITMEYER - 03 Jan 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 18:00:35 UTC
Previous filing
24 Jun 2021
Next filing
24 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Award $0 +128,557 +50% $0.000000 384,149 03 Jan 2022 Direct F1
transaction ONCT Common Stock Award $0 +6,793 $0.000000 6,793 03 Jan 2022 By Spouse F1
holding ONCT Common Stock 733 03 Jan 2022 By Child
holding ONCT Common Stock 21,544 03 Jan 2022 By Family Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Recipient's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan).

Remarks:

Exhibit 24 - Power of Attorney